{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T19:45:41Z","timestamp":1789933541075,"version":"4.0.1"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,4,7]],"date-time":"2016-04-07T00:00:00Z","timestamp":1459987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The availability of tyrosine kinase inhibitors has extended therapeutic options for chronic myeloid leukaemia (<jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content>) patients. Monitoring recommendations and clinical response goals have recently been updated. The objective of this study was to describe the profile of <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content> patients in chronic phase currently receiving first\u2010line therapy, including treatment, monitoring and response kinetics. A multicentre, cross\u2010sectional, epidemiological survey in unselected chronic phase <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content> patients in France attending consultations during a one\u2010month period was performed. 438 of 697 (62\u00b78%) reported patients were currently receiving first\u2010line treatment and were analysed. Imatinib was the most frequently received treatment (72\u00b74% of patients). Retrospective cytogenetic and molecular assessments at 3, 6, 12 or 18\u00a0months were available in 88\u00b74% of patients. At the 12\u2010month assessment, 32\u00b72% were not in major molecular response (<jats:styled-content style=\"fixed-case\">MMR<\/jats:styled-content>). At last assessment, among 355 patients with duration of treatment \u2265 12\u00a0months, 91\u00b75% had achieved <jats:styled-content style=\"fixed-case\">MMR<\/jats:styled-content> and 66\u00b75% were in deep molecular response. This study, performed in everyday practice population of <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content> patients, suggests that monitoring of molecular responses in real\u2010life practice is aligned with European LeukaemiaNet recommendations. The majority of patients still receiving first\u2010line treatment are in optimal response, with a few being classified as in the warning area or responding to failure.<\/jats:p>","DOI":"10.1111\/bjh.14022","type":"journal-article","created":{"date-parts":[[2016,4,10]],"date-time":"2016-04-10T17:38:34Z","timestamp":1460309914000},"page":"71-80","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of <scp>ELN<\/scp> recommendations in the management of first\u2010line treated chronic myeloid leukaemia patients: a French cross\u2010sectional study"],"prefix":"10.1111","volume":"174","author":[{"given":"Gabriel","family":"Etienne","sequence":"first","affiliation":[{"name":"Institut Bergoni\u00e9 Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Huguet","sequence":"additional","affiliation":[{"name":"Institut Universitaire du Cancer Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Guerci\u2010Bresler","sequence":"additional","affiliation":[{"name":"H\u00f4pital de Brabois Vandoeuvre\u2010Les\u2010Nancy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck E.","family":"Nicolini","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Lyon Sud Pierre Benite France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Maloisel","sequence":"additional","affiliation":[{"name":"Clinique Sainte\u2010Anne, HLA group Strasbourg France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Coiteux","sequence":"additional","affiliation":[{"name":"H\u00f4pital Claude Huriez Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dauriac","sequence":"additional","affiliation":[{"name":"H\u00f4pital Pontchaillou Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Carpentier","sequence":"additional","affiliation":[{"name":"Laboratoires Novartis France Rueil\u2010Malmaison France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bourdeix","sequence":"additional","affiliation":[{"name":"Laboratoires Novartis France Rueil\u2010Malmaison France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Tulliez","sequence":"additional","affiliation":[{"name":"CHU Henri Mondor Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Cony\u2010Makhoul","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Annecy Genevois Pringy France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,4,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"e_1_2_8_3_1","first-page":"6041","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani M.","year":"2009","journal-title":"Journal of Oncology"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.741577"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.85"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.10.019"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047266"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-510396"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511592"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080689"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22523"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1988"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.6565"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903479299"},{"key":"e_1_2_8_18_1","unstructured":"National Comprehensive Cancer Network.2014.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Chronic Meylogenous Leukemia. V.3.2014. Available at:http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp. Accessed 27 October 2015."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/asheducation-2013.1.176","article-title":"Update on current monitoring recommendations in chronic myeloid leukemia: practical points for clinical practice","volume":"2013","author":"Oehler V.G.","year":"2013","journal-title":"Hematology American Society of Hematology Education Program"},{"key":"e_1_2_8_21_1","first-page":"1695","article-title":"Survey of the frontline treatment and management of chronic myeloid leukemia (CML) in a real\u2010word setting: Third annual update of the Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (the WORLD CML Registry)","volume":"118","author":"Pasquini R.","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.974046"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2009.07.007"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1046"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14022","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T01:27:36Z","timestamp":1696296456000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,7]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1111\/bjh.14022"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14022","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,7]]},"assertion":[{"value":"2015-11-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-01-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-04-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}